ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 13:38:47 ON 16 FEB 2007)

     FILE 'REGISTRY' ENTERED AT 13:39:10 ON 16 FEB 2007
L1             STRUCTURE UPLOADED
L2           0 S L1 SSS SAM
L3           0 S L1 FULL
L4             STRUCTURE UPLOADED
L5           0 S L4 SSS SAM
L6           5 S L4 FULL

     FILE 'CAPLUS' ENTERED AT 13:42:10 ON 16 FEB 2007
L7           7 S L6

     FILE 'REGISTRY' ENTERED AT 13:44:27 ON 16 FEB 2007
L8             STRUCTURE UPLOADED
L9           0 S L8 SSS SAM
L10          4 S L8 FULL

     FILE 'CAPLUS' ENTERED AT 13:45:02 ON 16 FEB 2007
L11          3 S L10
```

C:\Program Files\Stnexp\Queries\10519979.str





chain nodes :
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
chain bonds :
1-25 4-27 8-18 9-28 10-26 12-33 13-35 13-37 14-36 14-38 15-39 16-40 17-29 19-32 20-31 21-24 22-30 33-34
ring bonds :
1-2 1-6 2-3 2-16 3-4 3-23 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14 14-15 15-16 15-23 17-18 17-22 18-19 19-20 20-21 21-22
exact/norm bonds :
1-25 2-16 3-23 5-7 6-10 7-8 8-9 9-10 10-26 11-12 11-16 12-13 13-14 13-37 14-15 14-38 15-16 15-23 21-24
exact bonds :
4-27 8-18 9-28 12-33 13-35 14-36 15-39 16-40 17-29 19-32 20-31 22-30 33-34
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

C:\Program Files\Stnexp\Queries\10519979a.str





chain nodes :
24 25 26 27 28 29 30 31 32 33 34
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
chain bonds :
1-25 8-18 10-26 12-27 13-29 13-31 14-30 14-32 15-33 16-34 21-24 27-28
ring bonds :
1-2 1-6 2-3 2-16 3-4 3-23 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14 14-15 15-16 15-23 17-18 17-22 18-19 19-20 20-21 21-22
exact/norm bonds :
1-25 2-16 3-23 5-7 6-10 7-8 8-9 9-10 10-26 11-12 11-16 12-13 13-14 13-31 14-15 14-32 15-16 15-23 21-24
exact bonds :
8-18 12-27 13-29 14-30 15-33 16-34 27-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS

C:\Program Files\Stnexp\Queries\10519979b.str





chain nodes :
23 24 25 26 27 28 30 31 32 33
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 29
chain bonds :
1-24 8-18 10-25 11-30 12-31 13-26 13-32 15-27 16-28 21-23 32-33
ring bonds :
1-2 1-6 2-3 3-4 3-29 4-5 4-15 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14 14-15 15-16 16-29
17-18 17-22 18-19 19-20 20-21 21-22
exact/norm bonds :
1-24 3-29 4-15 5-7 6-10 7-8 8-9 9-10 10-25 11-12 11-16 11-30 12-13 12-31 13-14 14-15 15-16 16-29
21-23
exact bonds :
8-18 13-26 13-32 15-27 16-28 32-33
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom
15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:CLASS 28:CLASS 29:Atom 30:CLASS 31:CLASS 32:CLASS 33:CLASS

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal600txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 8	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 13	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 14	DEC 18	CA/CAplus patent kind codes updated
NEWS 15	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 17	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 19	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 22	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 23	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 24	JAN 29	PHAR reloaded with new search and display fields
NEWS 25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 26	FEB 13	CASREACT coverage to be extended
NEWS 27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 28	Feb 15	RUSSIAPAT enhanced with pre-1994 records

NEWS EXPRESS	NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:38:47 ON 16 FEB 2007

=> file reg

McIntosh

```
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 13:39:10 ON 16 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 FEB 2007  HIGHEST RN 921436-24-0
DICTIONARY FILE UPDATES:  15 FEB 2007  HIGHEST RN 921436-24-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10519979.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 13:39:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      100 TO ITERATE

100.0% PROCESSED      100 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1401 TO     2599
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:39:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     2042 TO ITERATE

100.0% PROCESSED     2042 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

L3            0 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10519979a.str

L4      STRUCTURE UPLOADED

=> s l4 sss sam
SAMPLE SEARCH INITIATED 13:41:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      100 TO ITERATE

100.0% PROCESSED      100 ITERATIONS                              0 ANSWERS
```

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1401 TO 2599
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s l4 full
FULL SEARCH INITIATED 13:41:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2042 TO ITERATE

100.0% PROCESSED 2042 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

L6 5 SEA SSS FUL L4

=> d scan 1-5 l6
'1-5' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

L6 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-methoxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI)
MF C22 H20 O9

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)

IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L6 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-11-methoxy-3,4-bis(phenylmethoxy)-2-[(phenylmethoxy)methyl]-8-[4-(phenylmethoxy)phenyl]-, (2R,3R,4S,4aR,11bS)-(9CI)
MF C50 H44 O9

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-[4-(methoxymethoxy)phenyl]-, (2R,3S,4S,4aS,11bS)- (9CI)
MF C23 H22 O10

Absolute stereochemistry.



McIntosh

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-11-methoxy-8-(4-methoxyphenyl)-3,4-bis(phenylmethoxy)-2-[(phenylmethoxy)methyl]-, (2R,3R,4S,4aR,11bS)- (9CI)
MF C44 H40 O9

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI)
MF C21 H18 O9

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	345.55	345.76

FILE 'CAPLUS' ENTERED AT 13:42:10 ON 16 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 16 Feb 2007 VOL 146 ISS 9
FILE LAST UPDATED: 15 Feb 2007 (20070215/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

(FILE 'HOME' ENTERED AT 13:38:47 ON 16 FEB 2007)

FILE 'REGISTRY' ENTERED AT 13:39:10 ON 16 FEB 2007
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 0 S L1 FULL
L4 STRUCTURE UPLOADED
L5 0 S L4 SSS SAM
L6 5 S L4 FULL

FILE 'CAPLUS' ENTERED AT 13:42:10 ON 16 FEB 2007

=> s l6
L7 7 L6

=> d bib abs hitstr 1-7 l7

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1332639 CAPLUS
DN 146:42084
TI Antitumors isolated from oolong tea leaf
IN Wakabayashi, Keiji; Nukatani, Haruo; Muto, Tomohiro
PA National Cancer Center, Japan
SO Jpn. Kokai Tokkyo Koho, 18pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2006342103	A	20061221	JP 2005-169262	20050609
PRAI	JP 2005-169262		20050609		

AB The antitumoric OTAC (Oolong tea active compound), flavone derivs., are extracted from Oolong tea leaf. The antitumoric OTAC are able to inhibit cancer in rat colonic aberrant crypt foci (ACF model) and colonic polyp-formation Apc gene-deficient mouse model. Extraction of the antitumoric OTAC from the oolong tea leaf with hot water and inhibition of cancer in the two animal models were shown.
IT 720684-57-1P
RL: FFD (Food or feed use); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(OTAC antitumors isolated from oolong tea leaf)
RN 720684-57-1 CAPLUS
CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



McIntosh

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:441728 CAPLUS
DN 145:347946
TI Inhibition of intestinal carcinogenesis by a new flavone derivative, Chafuroside, in oolong tea
AU Niho, Naoko; Mutoh, Michihiro; Sakano, Katsuhisa; Takahashi, Mami; Hirano, Sachiko; Nukaya, Haruo; Sugimura, Takashi; Wakabayashi, Keiji
CS Cancer Prevention Basic Research Project, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
SO Cancer Science (2006), 97(4), 248-251
CODEN: CSACCM; ISSN: 1347-9032
PB Blackwell Publishing Asia Pty Ltd.
DT Journal
LA English
AB A new flavone derivative, Chafuroside, has been isolated as a strong anti-inflammatory compound from oolong tea leaves, and its structure determined to be (2R,3S,4S,4aS,11bS)-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-3,4,4a,11b-tetrahydro-2H,10H-pyrano[2',3':4,5]furo[3,2-g]chromen-10-one. To assess its potential to inhibit intestinal carcinogenesis, 2.5, 5, and 10 ppm Chafuroside was given in the diet to Apc-deficient Min mice for 14 wk from 6 wk of age. Total nos. of polyps were reduced to 83, 73,and 56% of the control value, resp. Moreover, dietary administration at 10 and 20 ppm reduced azoxymethane (AOM)-induced colon aberrant crypt foci (ACF) development in rats to 69% of the AOM-treated control value with the higher dose. Chafuroside-associated toxicity was not observed at 2.5-10 ppm in Min mice and 10-20 ppm in AOM-treated rats. These results suggest that Chafuroside might be a good chemopreventive agent for colon cancer.
IT 720684-57-1, Chafuroside
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of intestinal carcinogenesis by Chafuroside in oolong tea)
RN 720684-57-1 CAPLUS
CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1196260 CAPLUS
DN 143:440151
TI Preparation of flavone C glycoside
IN Tsuji, Kunio; Tanaka, Kei; Nukatani, Haruo; Furuta, Takumi
PA Japan Science and Technology Agency, Japan
SO Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2005314260	A	20051110	JP 2004-132592	20040428
PRAI	JP 2004-132592		20040428		
OS	MARPAT 143:440151				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compound I, which was isolated as antiallergy agent from oolong tea extract, is prepared by condensation of resorcinols II [R1, R2 = H, protecting group; R3 = (protected) OH, ether group, ester group; R4 = H, CO; when R3 = ether group and R4 = CO; then R3R4 may form (un)substituted ring] with sugars III (R5 = H, protecting group; R6 = halo, OC:NHCX3; X = halo) in the presence of Lewis acid catalysts in aprotic solvents and by treatment of C glycosides IV (R7, R8 = similar group as in R1, R2; R9, R10 = similar group as in R3, R4) with azodicarboxamide or azodicarboxylate esters and trialkylphosphine, triarylphosphine, or phosphoranes in aprotic solvents. Thus, 4-benzyloxy-2,6-dihydroxyacetophenone was treated with O-(2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyloxy)trichloroacetimidate in the presence of TMSOTf in CH2Cl2, esterified with 4-methoxymethoxybenzoic acid, cyclized, debenzylated, treated with TMAD and Bu3P in THF, and deprotected to give I.

IT 791601-83-7P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of flavone C glycoside from resorcinols and sugars)

RN 791601-83-7 CAPLUS

CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-[4-(methoxymethoxy)phenyl]-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 720684-57-1P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of flavone C glycoside from resorcinols and sugars)

RN 720684-57-1 CAPLUS

CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1103788 CAPLUS

DN 143:386847

TI Process for producing flavone c glycoside derivatives

IN Tsuji, Kuniro; Nukaya, Haruo

PA Suntory Limited, Japan

SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005095416	A1	20051013	WO 2005-JP5695	20050328
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2005289888	A	20051020	JP 2004-107760	20040331
	CA 2561401	A1	20051013	CA 2005-2561401	20050328
	EP 1731522	A1	20061213	EP 2005-721621	20050328
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	JP 2004-107760	A	20040331		
	WO 2005-JP5695	W	20050328		

GI



I



II

AB This invention provided a process for efficiently producing a flavone C glycoside derivative represented by the formula I which is an antiallergic substance or its salt, or a flavone C glycoside derivative represented by the formula II or its salt. I and II can be easily and efficiently synthesized by using isovitexin and vitexin contained in herbs and so on as the starting materials reacted in the presence of dehydrating agent, such as 1,1'-azobis[N,N-dimethylformamide] and tri-n-butylphosphine.

IT 720684-57-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of flavone c glycoside derivs. by cyclization of (iso)vitexin)

RN 720684-57-1 CAPLUS

CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:902389 CAPLUS
DN 141:380099
TI Flavone derivatives and process for producing them
IN Nakatsuka, Takashi
PA Daiichi Suntory Pharma Co., Ltd., Japan; Daiichi Suntory Biomedical Research Co., Ltd.
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004092180	A1	20041028	WO 2004-JP5451	20040416
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2006176407	A	20060706	JP 2003-113976	20030418
PRAI	JP 2003-113976	A	20030418		
OS	MARPAT 141:380099				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A process for the production of flavone derivs. I [R1a, R1b, R1c, R1m and R1n = H, OH, etc.], intermediates for the production thereof; and processes for producing the intermediates were disclosed. Further, the invention provides compds. I [R1a, R1b, R1c, R1m and R1n = H, OH, etc.], (with the proviso that the compound wherein R1c is OH, R1a, R1b, R1m, and R1n are hydrogen, and the sugar moiety is D-mannose is excepted), pharmacol. acceptable salts thereof, and pharmaceutical compns. containing both. For example, treatment of a mixture of compound II, III (35 mg), e.g., prepared from Me 3,4,5-tri-O-benzyl-2-O-p-nitrobenzyl-D-glucopyranoside in 10 steps, with trimethylsilyl triflate at room temperature for 10 min afforded compound IV [R1a = R1b = R1c = R1m = R1n = H] (8 mg), converted to compound I [R1a = R1b = R1c = R1m = R1n = H] using BCl3. In contact dermatitis control test, compound I [R1a = R1b = R1c = R1m = R1n = H] exhibited $p<0.05$ (Dunnett's test) at ≥2 μg/kg dose. Disclosed compds. I are claimed useful for the treatment of inflammation, allery. Formulation is given.

IT 780789-07-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(flavone scaffold preparation using iodobenzene diacetate)

RN 780789-07-3 CAPLUS
CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-11-methoxy-8-(4-methoxyphenyl)-3,4-bis(phenylmethoxy)-2-[(phenylmethoxy)methyl]-, (2R,3R,4S,4aR,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 720684-64-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(flavone scaffold preparation via heterocyclization using trimethylsilyl triflate)
RN 720684-64-0 CAPLUS
CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-11-methoxy-3,4-bis(phenylmethoxy)-2-[(phenylmethoxy)methyl]-8-[4-(phenylmethoxy)phenyl]-, (2R,3R,4S,4aR,11bS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 720684-57-1P 780789-12-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of flavone derivs. for treatment of inflammation, allergy)
RN 720684-57-1 CAPLUS
CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 780789-12-0 CAPLUS
CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-methoxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:769344 CAPLUS
DN 141:411155
TI Concise total synthesis of flavone C-glycoside having potent anti-inflammatory activity
AU Furuta, Takumi; Kimura, Tomoyuki; Kondo, Sachiko; Mihara, Hisashi; Wakimoto, Toshiyuki; Nukaya, Haruo; Tsuji, Kuniro; Tanaka, Kiyoshi
CS School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, 422-8526, Japan
SO Tetrahedron (2004), 60(42), 9375-9379
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 141:411155
AB The total synthesis of anti-inflammatory active flavone C-glycoside isolated from oolong tea extract is achieved. Introducing a C-glucosyl moiety to an aryl system and constructing a fused tetracyclic ring characteristic to this natural product were conducted based on the O-to-C rearrangement of sugar moiety and the successive intramol. Mitsunobu reaction, resp. This concise and efficient synthetic pathway is applicable to the large-scale synthesis of target flavone and for constructing a large library of related compds.
IT 791601-83-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of the anti-inflammatory active flavone C-glycoside isolated from oolong tea extract via rearrangement and intramol. Mitsunobu reaction)
RN 791601-83-7 CAPLUS
CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-[4-(methoxymethoxy)phenyl]-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 720684-57-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of the anti-inflammatory active flavone C-glycoside isolated from oolong tea extract via rearrangement and intramol. Mitsunobu reaction)
RN 720684-57-1 CAPLUS
CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:403848 CAPLUS
DN 141:106296
TI First total synthesis of structurally unique flavonoids and their strong anti-inflammatory effect
AU Nakatsuka, Takashi; Tomimori, Yoshiaki; Fukuda, Yoshiaki; Nukaya, Haruo
CS Daiichi Suntory Biomedical Research Co., Ltd., Mishima-gun, Osaka, 618-8513, Japan
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(12), 3201-3203
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 141:106296
GI



I

AB The first total synthesis of structurally unique flavonoids I (R = OH, H) is described. These compds. showed very strong anti-inflammatory effect against delayed hypersensitivity in a mouse model.
IT 720684-57-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of fused tricyclic flavonoids from a D-glucal and their strong anti-inflammatory effect)
RN 720684-57-1 CAPLUS
CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-, (2R,3S,4S,4aS,11bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 720684-64-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused tricyclic flavonoids from a D-glucal and their strong anti-inflammatory effect)
RN 720684-64-0 CAPLUS
CN 2H,10H-Pyrano[2',3':4,5]furo[3,2-g][1]benzopyran-10-one, 3,4,4a,11b-tetrahydro-11-methoxy-3,4-bis(phenylmethoxy)-2-[(phenylmethoxy)methyl]-8-[4-(phenylmethoxy)phenyl]-, (2R,3R,4S,4aR,11bS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	38.77	384.53
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.46	-5.46

FILE 'REGISTRY' ENTERED AT 13:44:27 ON 16 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 FEB 2007 HIGHEST RN 921436-24-0
DICTIONARY FILE UPDATES: 15 FEB 2007 HIGHEST RN 921436-24-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10519979b.str

L8 STRUCTURE UPLOADED

=> s l8 sss sam
SAMPLE SEARCH INITIATED 13:44:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 100 TO ITERATE

100.0% PROCESSED 100 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          1401 TO     2599
PROJECTED ANSWERS:                0 TO        0

L9            0 SEA SSS SAM L8

=> s l8 full
FULL SEARCH INITIATED 13:44:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      2042 TO ITERATE

100.0% PROCESSED     2042 ITERATIONS                              4 ANSWERS
SEARCH TIME: 00.00.01

L10           4 SEA SSS FUL L8

=> file caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 172.10     556.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                   0.00      -5.46

FILE 'CAPLUS' ENTERED AT 13:45:02 ON 16 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 16 Feb 2007  VOL 146 ISS 9
FILE LAST UPDATED: 15 Feb 2007  (20070215/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l10
L11           3 L10

=> d bib abs hitstr 1-3 l11

L11  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:1332639  CAPLUS
DN   146:42084
TI   Antitumors isolated from oolong tea leaf
IN   Wakabayashi, Keiji; Nukatani, Haruo; Muto, Tomohiro
PA   National Cancer Center, Japan
SO   Jpn. Kokai Tokkyo Koho, 18pp.
     CODEN: JKXXAF
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     ---------------     ----   --------   --------------------   --------
PI   JP 2006342103        A     20061221   JP 2005-169262         20050609
PRAI JP 2005-169262               20050609
AB   The antitumoric OTAC (Oolong tea active compound), flavone derivs., are
     extracted from Oolong tea leaf.  The antitumoric OTAC are able to inhibit
     cancer in rat colonic aberrant crypt foci (ACF model) and colonic
     polyp-formation Apc gene-deficient mouse model.  Extraction of the antitumoric
     OTAC from the oolong tea leaf with hot water and inhibition of cancer in
     the two animal models were shown.
```

IT 866737-00-0P
RL: FFD (Food or feed use); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(OTAC antitumors isolated from oolong tea leaf)
RN 866737-00-0 CAPLUS
CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one, 7a,9,10,11a-tetrahydro-5,8,9-trihydroxy-10-(hydroxymethyl)-2-(4-hydroxyphenyl)-, (7aS,8S,9S,10R,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:36756 CAPLUS
DN 144:108139
TI Preparation of flavones, their medial compositions, and their use as antiallergy and anti-inflammatory agents
IN Nakatsuka, Takashi; Nimura, Junko
PA Daiichi Asbio Pharma Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 53 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2006008626	A	20060112	JP 2004-190367	20040628
PRAI	JP 2004-190367		20040628		

OS MARPAT 144:108139
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Flavones I [R1a-R1e = H, OH, C1-6 linear or branched alkyl(oxy), halo] and their their pharmacol. acceptable salts are prepared from p-azidobenzyloxyfluoropyrans II (R3a-xirc = protecting group) and 2-hydroxyacetophenones III (R3d, R3e = protecting group) in the presence of Lewis acids via IV (R3a-R3e = protecting group; R3f = p-nitrobenzyl, p-azidobenzyl). Thus, cyclization of 8-[(2S,3S,4R,5R,6R)-4,5-bis(benzyloxy)-6-benzyloxymethyl-3-hydroxytetrahydro-2H-pyran-2-yl]-5,7-dihydroxy-2-phenyl-4H-chromen-4-one gave (7aR,8S,9R,10R,11aS)-8,9-bis(benzyloxy)-10-(benzyloxy)methyl-5-hydroxy-2-phenyl-7a,9,10,11a-tetrahydro-4H,8H-pyrano[2',3':4,5]furo[2,3-h]chromen-4-one, which was deprotected to afford the corresponding flavone derivative The product inhibited the ear swelling of in mice with TNCB-induced contact dermatitis in a dose-dependent manner.
IT 866737-00-0P 873077-63-5P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of flavones as antiallergy and anti-inflammatory agents)

RN 866737-00-0 CAPLUS
CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one, 7a,9,10,11a-tetrahydro-5,8,9-trihydroxy-10-(hydroxymethyl)-2-(4-hydroxyphenyl)-, (7aS,8S,9S,10R,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 873077-63-5 CAPLUS
CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one, 7a,9,10,11a-tetrahydro-5,8,9-trihydroxy-10-(hydroxymethyl)-2-(4-methoxyphenyl)-, (7aS,8S,9S,10R,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 873077-34-0P 873077-51-1P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of flavones as antiallergy and anti-inflammatory agents)
RN 873077-34-0 CAPLUS
CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one, 7a,9,10,11a-tetrahydro-5-hydroxy-2-(4-hydroxyphenyl)-8,9-bis(phenylmethoxy)-10-[(phenylmethoxy)methyl]-, (7aR,8S,9R,10R,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 873077-51-1 CAPLUS
CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one, 7a,9,10,11a-tetrahydro-5-hydroxy-2-(4-methoxyphenyl)-8,9-bis(phenylmethoxy)-10-[(phenylmethoxy)methyl]-, (7aR,8S,9R,10R,11aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1103788 CAPLUS
DN 143:386847
TI Process for producing flavone c glycoside derivatives
IN Tsuji, Kuniro; Nukaya, Haruo
PA Suntory Limited, Japan
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005095416	A1	20051013	WO 2005-JP5695	20050328
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,				

MR, NE, SN, TD, TG

JP 2005289888	A	20051020	JP 2004-107760	20040331
CA 2561401	A1	20051013	CA 2005-2561401	20050328
EP 1731522	A1	20061213	EP 2005-721621	20050328

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRAI JP 2004-107760 A 20040331
WO 2005-JP5695 W 20050328

GI



I



II

AB This invention provided a process for efficiently producing a flavone C glycoside derivative represented by the formula I which is an antiallergic substance or its salt, or a flavone C glycoside derivative represented by the formula II or its salt. I and II can be easily and efficiently synthesized by using isovitexin and vitexin contained in herbs and so on as the starting materials reacted in the presence of dehydrating agent, such as 1,1'-azobis[N,N-dimethylformamide] and tri-n-butylphosphine.

IT 866737-00-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of flavone c glycoside derivs. by cyclization of (iso)vitexin)

RN 866737-00-0 CAPLUS

CN 4H,8H-Pyrano[2',3':4,5]furo[2,3-h]-1-benzopyran-4-one, 7a,9,10,11a-tetrahydro-5,8,9-trihydroxy-10-(hydroxymethyl)-2-(4-hydroxyphenyl)-, (7aS,8S,9S,10R,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD